@article{oai:nagasaki-u.repo.nii.ac.jp:00001598,
 author = {Itonaga, Hidehiro and Ishiyama, Ken and Aoki, Kazunari and Aoki, Jun and Ishikawa, Takayuki and Ohashi, Kazuteru and Fukuda, Takayuki and Ozawa, Yukiyasu and Ota, Shuichi and Uchida, Naoyuki and Eto, Tetsuya and Iwato, Koji and Ohno, Yuju and Takanashi, Minoko and Ichinohe, Tatsuo and Atsuta, Yoshiko and Miyazaki, Yasushi},
 issue = {9},
 journal = {Bone Marrow Transplantation},
 month = {Feb},
 note = {We conducted a nationwide retrospective study to evaluate the prognostic influence of +1, der(1;7)(q10;p10) [hereafter der(1;7)] and ?7/del(7q) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for de novo myelodysplastic syndromes (MDS). In this database, 69 MDS patients with der(1;7), 75 with ?7/del(7q),
 and 511 with normal karyotype (NK) underwent allo-HSCT at advanced disease status. The 3-year overall survival (OS) 
and cumulative incidence of relapse (CIR) were 50.4 and 19.4% for those with der(1;7), 36.2 and 38.4% for ?7/del(7q),and 51.1 and 20.7% for NK, respectively. In the multivariate analysis, the presence of ?7/del(7q) correlated with a significantly shorter OS (HR [95% CI], 1.38 [1.00?1.89]; P = 0.048) and higher CIR (HR, 2.11 [1.36?3.28]; P = 0.001) than those with NK. There were 23 patients with der(1;7), 29 with ?7/del(7q), and 347 with NK who underwent allo-HSCT at early disease status.The 3-year OS and CIR were as follows: 47.3 and 9.5% for the der(1;7) group, 70.5 and 13.8% for ?7/del(7q), and 70.9 and 5.6% for NK,respectively. No significant differences were observed in OS and CIR among three groups. The impact of the loss of chromosome 7q on OS and CIR may differ based on its type and disease status after allo-HSCT for MDS., Bone Marrow Transplantation, 54(9), pp.1471-1481; 2019},
 pages = {1471--1481},
 title = {Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation},
 volume = {54},
 year = {2019}
}